Latest News and Press Releases
Want to stay updated on the latest news?
-
– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American...
-
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that...
-
JERUSALEM, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the...
-
-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT™ in recurrent cutaneous squamous cell carcinoma....
-
JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and...
-
JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
-
TEL AVIV, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical is happy to announce its first clinical trial in Italy. The study at IRST, Meldola, will evaluate the feasibility, safety and...
-
TEL AVIV, Israele, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical è lieta di annunciare l’avvio della sua prima sperimentazione clinica in Italia. Lo studio che sarà condotto presso l’IRST, a...